Skip to Content

Drug interactions between Bydureon and Victoza

Results for the following 2 drugs:
Bydureon (exenatide)
Victoza (liraglutide)

Interactions between your drugs

There were no interactions found in our database between Bydureon and Victoza. However, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Bydureon

A total of 797 drugs (5361 brand and generic names) are known to interact with Bydureon.

Victoza

A total of 681 drugs (5388 brand and generic names) are known to interact with Victoza.

Drug and food interactions

Moderate

exenatide food

Applies to: Bydureon (exenatide)

You should take exenatide twice a day, at any time within the 60 minutes (1 hour) before your morning and evening meals, or before the two main meals of the day, and at least 6 hours or more apart. You may experience decreased absorption of exenatide in the presence of food or other medications. Your other medications should be administered at least 1 hour before or 2 hours after your exenatide injection.

Switch to professional interaction data

Moderate

liraglutide food

Applies to: Victoza (liraglutide)

Liraglutide may affect the absorption of other medications that you take by mouth. In some cases, this may affect how well and/or how fast those medications work, or it may make no difference. Talk to a healthcare provider if you have any questions or concerns, and contact your doctor if your symptoms worsen or your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Incretin-based therapies

Therapeutic duplication

The recommended maximum number of medicines in the 'incretin-based therapies' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'incretin-based therapies' category:

  • exenatide (active ingredient in Bydureon (exenatide))
  • liraglutide (active ingredient in Victoza (liraglutide))

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide